Brickell Biotech Inc (BBI)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

5777 CENTRAL AVENUE BOULDER, CO 80301

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.

Data as of 2021-08-02 07:43:56 -0400
Market Cap58.686 Million Shares Outstanding84.929 Million Avg 30-day Volume1.523 Million
P/E Ratio-2.27333 Dividend Yield EPS-0.688
Price/Sales74.01 Debt to Equity1.33 EBITDA-25.871 Million
Price to Book Value2.01 Forward PE-0.79 Enterprise Value24.342 Million
Total Cash34.781 Million Current Debt9.381 Million Gross Profit793 Thousand
BETA0.74631 52-week High/Low1.7 / 0.466 Next Earnings Date2021-08-12 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from BBI instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 32 29 10.34% 11 (0.65%) 10 (0.58%) 10.0%
13F shares: 5.577 Million 5.638 Million -1.09% 3.356 Million 4.001 Million -16.12%
% Ownership 8.3323 10.5361 -20.92% 5.0138 7.4759 -32.93%
New Positions: 10 11 -9.09% 4 5 -20.0%
Increased Positions 13 6 116.67% 5 3 66.67%
Closed Positions 6 3 100.0% 3 2 50.0%
Reduced Positions 1 2 -50.0%
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BBI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BBI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

218.1 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCAVOY DAVID R. GENERAL COUNSEL AND CCO

  • Officer
142,859 2021-07-23 6

HARDY REGINALD L CHAIRMAN OF THE BOARD

  • Officer
  • Director
1,128,876 2021-07-23 5

SAMANT VIJAY B

  • Director
40,000 2021-06-14 4

LYONS GARY A

  • Director
40,000 2021-06-14 4

BRETON JOSE CHIEF ACCOUNTING OFFICER

  • Officer
85,000 2021-06-14 3

SKLAWER ANDREW D COO AND SECRETARY

  • Officer
250,000 2021-06-14 4

BROWN ROBERT BUSARD CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
750,000 2021-06-14 3

VERU DENNISON T

  • Director
40,000 2021-06-14 3

CHADHA DEEPAK CHIEF RESEARCH & DEV. OFFICER

  • Officer
250,000 2021-06-14 4

MARCHIO ALBERT N II CHIEF FINANCIAL OFFICER

  • Officer
20,000 2021-06-14 2

LEVY ADAM SCOTT CHIEF BUSINESS OFFICER

0 2020-03-16 0

CARRUTHERS R MICHAEL CHIEF FINANCIAL OFFICER

0 2020-03-16 0

ABERCROMBIE GEORGE B CHIEF EXECUTIVE OFFICER

138,424 2020-02-14 0

AHUJA SANJEEV CHIEF MEDICAL OFFICER

0 2019-11-04 0

JU WILLIAM

13,363 2019-08-31 0

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • 10% Owner
No longer subject to file 2019-01-10 0

DOUGLAS R GORDON

  • Director
0 2018-05-23 0

MERTON ROBERT C

  • Director
0 2018-05-23 0

MORROW GEORGE J

  • Director
0 2018-05-23 0

BELESON RICHARD M

  • Director
0 2018-05-23 0

SHENK THOMAS E

  • Director
0 2018-05-23 0

RAMOS ANTHONY ALAN VP, CHIEF FINANCIAL OFFICER

  • Officer
0 2018-01-08 0

SMITH LAWRENCE RUSSELL SR VP, RESEARCH

  • Officer
0 2018-01-08 0

MAMMEN MAMMEN SR VP, CLINICAL DEVELOPMENT

  • Officer
0 2018-01-08 0

ANGES MG, INC.

2,058,528 2016-08-02 0

BILINSKY IGOR SR VP, CORPORATE DEVELOPMENT

  • Officer
193,798 2015-07-13 0

SHERWIN STEPHEN A

  • Director
22,003 2015-05-21 0

SINGER JAMES R

  • 10% Owner
No longer subject to file 2013-09-12 0

ROLLAND ALAIN P PHD EXEC VP, PRODUCT DEVELOPMENT

  • Officer
No longer subject to file 2013-08-22 0

BROADFOOT JILL MARIE SR VICE PRESIDENT, CFO, SEC

  • Officer
No longer subject to file 2013-04-01 0

CAMPBELL ROBERT H

  • Director
14,328 2012-10-19 0

MARXE AUSTIN W & GREENHOUSE DAVID M

  • 10% Owner
No longer subject to file 2009-07-24 0

V-SCIENCES INVESTMENTS PTE LTD

TEMASEK LIFE SCIENCES PRIVATE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
No longer subject to file 2009-05-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HARDY REGINALD L - Director - Officer CHAIRMAN OF THE BOARD

2021-07-27 16:43:06 -0400 2021-07-26 P 100,000 $0.67 a 448,411 direct -1.4514 0.0 1 -1.4514 2

HARDY REGINALD L - Director - Officer CHAIRMAN OF THE BOARD

2021-07-27 16:43:06 -0400 2021-07-23 P 100,000 $0.66 a 348,411 direct -1.4514 0.0 1 -1.4514 2

MCAVOY DAVID R. - Officer GENERAL COUNSEL AND CCO

2021-07-27 16:42:16 -0400 2021-07-23 P 18,124 $0.67 a 128,879 direct -1.4514 0.0 1 -1.4514 2

CHADHA DEEPAK - Officer CHIEF RESEARCH & DEV. OFFICER

2021-06-14 16:45:02 -0400 2021-06-14 A 250,000 a 250,000 direct

MARCHIO ALBERT N II - Officer CHIEF FINANCIAL OFFICER

2021-06-14 16:46:03 -0400 2021-06-14 A 20,000 a 20,000 direct

VERU DENNISON T - Director

2021-06-14 16:47:14 -0400 2021-06-14 A 40,000 a 40,000 direct

BROWN ROBERT BUSARD - Director - Officer CHIEF EXECUTIVE OFFICER

2021-06-14 16:44:20 -0400 2021-06-14 A 750,000 a 750,000 direct

BRETON JOSE - Officer CHIEF ACCOUNTING OFFICER

2021-06-14 16:46:27 -0400 2021-06-14 A 85,000 a 85,000 direct

LYONS GARY A - Director

2021-06-14 16:43:31 -0400 2021-06-14 A 40,000 a 40,000 direct

SAMANT VIJAY B - Director

2021-06-14 16:44:36 -0400 2021-06-14 A 40,000 a 40,000 direct

SKLAWER ANDREW D - Officer COO AND SECRETARY

2021-06-14 16:45:38 -0400 2021-06-14 A 250,000 a 250,000 direct

HARDY REGINALD L - Director - Officer CHAIRMAN OF THE BOARD

2021-06-14 16:46:49 -0400 2021-06-14 A 40,000 a 40,000 direct

MCAVOY DAVID R. - Officer GENERAL COUNSEL AND CCO

2021-06-14 16:43:57 -0400 2021-06-14 A 200,000 a 200,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BRICKELL BIOTECH INC BBI 2021-08-03 15:15:03 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-03 14:45:04 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-03 14:15:03 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-03 13:45:03 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-03 13:15:03 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-03 12:45:03 UTC -20.2791 20.3391 1700000
BRICKELL BIOTECH INC BBI 2021-08-02 22:15:03 UTC -20.2791 20.3391 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 21:45:03 UTC -20.2791 20.3391 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 21:15:03 UTC -20.2791 20.3391 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 20:45:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 20:15:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 19:45:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 19:15:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 18:45:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 18:15:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 17:45:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 17:15:03 UTC -20.4106 20.4706 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 16:45:03 UTC -20.4122 20.4922 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 16:15:03 UTC -20.4122 20.4922 1600000
BRICKELL BIOTECH INC BBI 2021-08-02 15:45:03 UTC -20.4122 20.4922 1600000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments